A preclinical model of THC edibles that produces high-dose cannabimimetic responses

Background No preclinical approach enables the study of voluntary oral consumption of high dose Δ9-tetrahydrocannabinol (THC) and its intoxicating effects, mainly owing to the aversive response of rodents to THC that limits intake. Here we developed a palatable THC formulation and an optimized access paradigm in mice. Methods THC was formulated in chocolate gelatin (THC-E-gel). Adult male and female mice were allowed ad libitum access for 2 h. Cannabimimetic responses (hypolocomotion, analgesia, and hypothermia) were measured following access. Levels of THC and its metabolites were measured in blood and brain samples. Acoustic startle responses were measured to investigate THC-induced psychotomimetic behavior. Results Access to high-dose THC-E-gel (≈30 mg/kg over 2 h) resulted in robust consumption and CB1 receptor-dependent behavioral responses. High-dose THC-E-gel consumption resulted in parallel accumulation of THC and its psychoactive metabolite 11-OH-THC in brain, a profile that contrasts with the known rapid decline in brain 11-OH-THC levels following intraperitoneal THC injections. High-dose THC-E-gel consumption increased the acoustic startle response preferentially in males, and this psychotomimetic response was remarkably different from the response triggered by intraperitoneal contingent administration of THC. Comparing cannabimimetic responses elicited by intraperitoneal versus oral administration enabled us to model a “predicted dose” of THC that triggers these responses. Conclusion Voluntary consumption of high-dose THC-E-gel triggered equivalent cannabimimetic responses in male and female mice but an increased acoustic startle response preferentially in males. These findings indicate that THC-E-gel offers a robust preclinical consumption model to study cannabimimetic responses in mice, including sex-dependent psychotomimetic responses.

[1]  G. Schauer,et al.  Cannabis-only use in the USA: prevalence, demographics, use patterns, and health indicators , 2022, Journal of Cannabis Research.

[2]  C. D. Fowler,et al.  Pharmacokinetic and pharmacodynamic properties of aerosolized (“vaped”) THC in adolescent male and female rats , 2021, Psychopharmacology.

[3]  S. Anagnostaras,et al.  Quantifying the Acoustic Startle Response in Mice Using Standard Digital Video , 2020, Frontiers in Behavioral Neuroscience.

[4]  A. Das,et al.  Comparative Pharmacokinetics of Δ9-Tetrahydrocannabinol in Adolescent and Adult Male Mice , 2020, The Journal of Pharmacology and Experimental Therapeutics.

[5]  Cedric E. Ginestet,et al.  Psychiatric symptoms caused by cannabis constituents: a systematic review and meta-analysis , 2020, The lancet. Psychiatry.

[6]  K. Mackie,et al.  Self-administration of edible Δ9-tetrahydrocannabinol and associated behavioral effects in mice. , 2019, Drug and alcohol dependence.

[7]  J. Clark,et al.  Voluntary oral consumption of Δ9-tetrahydrocannabinol by adolescent rats impairs reward-predictive cue behaviors in adulthood , 2019, Neuropsychopharmacology.

[8]  D. Hasin,et al.  Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings , 2019, The American journal of drug and alcohol abuse.

[9]  Zeena M. G. Rivera,et al.  Orally consumed cannabinoids provide long-lasting relief of allodynia in a mouse model of chronic neuropathic pain , 2019, bioRxiv.

[10]  S. Boehm,et al.  Acute Cannabinoids Produce Robust Anxiety-Like and Locomotor Effects in Mice, but Long-Term Consequences Are Age- and Sex-Dependent , 2019, Front. Behav. Neurosci..

[11]  C. Morgan,et al.  Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function , 2018, Translational Psychiatry.

[12]  J. Wiley,et al.  Evaluation of reinforcing and aversive effects of voluntary Δ9-tetrahydrocannabinol ingestion in rats , 2018, Neuropharmacology.

[13]  I. Ibarra-Lecue,et al.  Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway , 2018, Neuropsychopharmacology.

[14]  F. Barrett,et al.  “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs , 2018, Cannabis and cannabinoid research.

[15]  P. Piazza,et al.  Cannabinoid‐Induced Tetrad in Mice , 2017, Current protocols in neuroscience.

[16]  Christopher M. Jones,et al.  Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. , 2016, The lancet. Psychiatry.

[17]  R. Dinis-Oliveira Metabolomics of Δ9-tetrahydrocannabinol: implications in toxicity , 2016, Drug metabolism reviews.

[18]  N. Ginovart,et al.  Repeated but not acute treatment with ∆9-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: Reversal by the dopamine D2/3 receptor antagonist haloperidol , 2014, European Neuropsychopharmacology.

[19]  J. Clark,et al.  Chronic alcohol intake during adolescence, but not adulthood, promotes persistent deficits in risk-based decision making. , 2014, Alcoholism, clinical and experimental research.

[20]  P. McGuire,et al.  Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. , 2012, Current pharmaceutical design.

[21]  Raquel E Gur,et al.  Age group and sex differences in performance on a computerized neurocognitive battery in children age 8-21. , 2012, Neuropsychology.

[22]  B. Platt,et al.  Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ9-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive–compulsive behaviour , 2011, Psychopharmacology.

[23]  D. Dow-Edwards,et al.  Sexually dimorphic alterations in locomotion and reversal learning after adolescent tetrahydrocannabinol exposure in the rat. , 2010, Neurotoxicology and teratology.

[24]  I. McGregor,et al.  A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. , 2010, The international journal of neuropsychopharmacology.

[25]  D. Selley,et al.  FAAH−/− Mice Display Differential Tolerance, Dependence, and Cannabinoid Receptor Adaptation After Δ9-Tetrahydrocannabinol and Anandamide Administration , 2010, Neuropsychopharmacology.

[26]  R. Maldonado,et al.  Delta-9-tetrahydrocannabinol enhances food reinforcement in a mouse operant conflict test , 2009, Psychopharmacology.

[27]  A F Cohen,et al.  Effect of intrapulmonary tetrahydrocannabinol administration in humans , 2008, Journal of psychopharmacology.

[28]  W. A. Wilson,et al.  Sex differences in the effects of Δ9-tetrahydrocannabinol on spatial learning in adolescent and adult rats , 2007, Behavioural pharmacology.

[29]  S. Puglisi‐Allegra,et al.  Prefrontal/accumbal catecholamine system determines motivational salience attribution to both reward- and aversion-related stimuli , 2007, Proceedings of the National Academy of Sciences.

[30]  Y. Shoyama,et al.  Antipsychotics improve Δ9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice , 2006, Pharmacology Biochemistry and Behavior.

[31]  A. Lichtman,et al.  Δ9-Tetrahydrocannbinol Accounts for the Antinociceptive, Hypothermic, and Cataleptic Effects of Marijuana in Mice , 2005, Journal of Pharmacology and Experimental Therapeutics.

[32]  K. Norén,et al.  Determination of Δ1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography–mass spectrometry , 1989 .

[33]  J. Scimeca,et al.  Studies on the agonistic activity of delta 9-11-tetrahydrocannabinol in mice, dogs and rhesus monkeys and its interactions with delta 9-tetrahydrocannabinol. , 1987, The Journal of pharmacology and experimental therapeutics.

[34]  L. Hollister,et al.  Delta‐8‐ and delta‐9‐tetrahydrocannabinol; Comparison in man by oral and intravenous administration , 1973, Clinical pharmacology and therapeutics.

[35]  J. Axelrod,et al.  Delta-9-Tetrahydrocannabinol: Localization in Body Fat , 1973, Science.

[36]  L. Hollister,et al.  Tetrahydrocannabinol Isomers and Homologues: Contrasted Effects of Smoking , 1970, Nature.

[37]  J. Jaffe,et al.  1-δ9-Tetrahydrocannabinol: Neurochemical and Behavioral Effects in the Mouse , 1969, Science.